Myelofibrosis Clinical Trials
Myelofibrosis Clinical Trials provide patients with early access to innovative and non-traditional treatment options such as immunotherapy, targeted therapy, and chemotherapy. Clinical trials explore new ways to prevent, detect, or treat diseases.
Myelofibrosis Clinical Trials are extremely important to further our knowledge of this disease. Myelofibrosis usually develops slowly. In the very early stages of the disease, many people do not experience signs or symptoms. As the deterioration of normal blood cell production increases, signs and symptoms are often experienced.
What Are Myelofibrosis Clinical Trials?
Many exciting new treatments are currently being tested through clinical trials run by experts. Research is expanding rapidly with a focus on drug types such as:
- Alternative JAK inhibitors
- Transfusion addiction agents
- Antifibrinolytic agents
- Telomerase inhibitors
- BET inhibitors
New strategies are being investigated by trying many drug combinations in clinical trials. These studies give hope for the future treatment of the disease. Clinical trials are a great alternative for patients who are not benefiting from other treatments.
Does Myelofibrosis Turn into Leukemia?
Myelofibrosis is a rare disease and can be seen in both men and women. People of all ages can have myelofibrosis, but it is more often diagnosed in people over the age of 50. The diagnosis of myelofibrosis is usually seen before the age of 3 in children.
Myelofibrosis, a rare type of blood cancer, is considered a type of chronic leukemia. Acute leukemia may develop in some patients with myelofibrosis. Acute myelogenous leukemia, a type of rapidly progressing blood and bone marrow cancer, is one of the complications of myelofibrosis.
Other complications that may arise from myelofibrosis include increased blood pressure in the liver (portal hypertension), abdominal and back pain due to enlargement of the spleen, and bleeding in the gastrointestinal system due to tumor formation.
Myelofibrosis Targeted Treatments
In 2005, the discovery of JAK2 mutations enabled the development of a targeted therapy for patients with myelofibrosis. The JAK1/JAK2 inhibitor, ruxolitinib, is the first FDA-approved drug for the treatment of myelofibrosis. Fedratinib is another drug that has also been approved as the first treatment option for high-risk myelofibrosis.
Interferon is an immune therapy that helps reduce the excess of unhealthy blood cells and cytokines that cause fibrosis in the bone marrow. However, there may be significant side effects of interferon that may be difficult to tolerate for some patients. If you are looking for alternative treatment options, it is important to consult your doctor before making any decisions.